Boston Scientific Corporation vs Roblox Corp — how do they compare? Boston Scientific Corporation trades at $43.23 (market cap $66.37B), while Roblox Corp trades at $56.69 (market cap $39.00B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Roblox Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | RBLX | |
|---|---|---|
Market Cap | $66.37B | $39.00B |
Sector | Health | Media |
52-Week High | $108.14 | $141.56 |
52-Week Low | $42.63 | $41.30 |
Enterprise Value | $75.94B | $37.59B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Roblox (RBLX) trades at $55.085, down 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.62. Revenue grew to $4.89 billion in 2025, though net losses persist at -$1.07 billion. The stock faces headwinds from multiple class-action lawsuits filed in July 2026 alleging securities fraud, but operational cash flow improved to $1.8 billion, supporting ongoing platform investments.
The outlook balances robust user growth and cash generation against profitability challenges and legal risks. Upside exists if monetization improves and legal issues resolve, but high P/B of 91.2 and negative margins warrant caution. Analysts remain predominantly bullish (51% buy ratings), viewing recent declines as a buying opportunity for long-term platform expansion.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →